2. Search Result
Search Result
Isoforms Recommended: PDE1
Results for "

PDE1A

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12501A
    ITI-214
    3 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease
    ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions [1] .
    ITI-214
  • HY-112831
    Osoresnontrine
    1 Publications Verification

    BI-409306

    		 Phosphodiesterase (PDE) Neurological Disease
    Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC50, 1.4 µM), PDE1C (IC50, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC50 all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.
    Osoresnontrine
  • HY-103493
    TAK-915

    		Phosphodiesterase (PDE) Neurological Disease
    TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment [1] .
    TAK-915
  • HY-136569
    DSR-141562

    		Phosphodiesterase (PDE) Neurological Disease
    DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia [1] .
    DSR-141562
  • HY-101490
    PDE1-IN-2

    		Phosphodiesterase (PDE) Neurological Disease
    PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders [1].
    PDE1-IN-2
  • HY-111167
    AN-2898

    		Phosphodiesterase (PDE) Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research [1].
    AN-2898
  • HY-RS10209
    Pde1a Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Pde1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pde1a Mouse Pre-designed siRNA Set A
    Pde1a Mouse Pre-designed siRNA Set A
  • HY-RS10210
    PDE1A Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PDE1A Rat Pre-designed siRNA Set A contains three designed siRNAs for PDE1A gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PDE1A Rat Pre-designed siRNA Set A
    PDE1A Rat Pre-designed siRNA Set A
  • HY-RS10208
    PDE1A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PDE1A Human Pre-designed siRNA Set A contains three designed siRNAs for PDE1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PDE1A Human Pre-designed siRNA Set A
    PDE1A Human Pre-designed siRNA Set A
  • HY-12501
    ITI-214 free base

    		Phosphodiesterase (PDE) Neurological Disease
    ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions [1] .
    ITI-214 free base
  • HY-120195
    PF-04677490

    		Phosphodiesterase (PDE) Neurological Disease
    PF-04677490 is a PDE1 inhibitor (IC50: 21 nM). PF-04677490 has IC50s of 21 nM, 83 nM, and 118 nM for PDE1B1, PDE1C, and PDE1A, respectively. PF-04677490 efficaciously inhibits cAMP- and cGMP-hydrolytic activity [1].
    PF-04677490
  • HY-120741
    PF-04822163

    		Phosphodiesterase (PDE) Neurological Disease
    PF-04822163 is an orally active, selective, and blood-brain barrier permeable PDE1 inhibitor with IC50 values of 2 nM, 2.4 nM, and 7 nM for PDE1A, PDE1B, and PDE1C respectively. PF-04822163 can be used in the research of attention deficit hyperactivity disorder or Parkinson's disease [1].
    PF-04822163
  • HY-147946
    PDE1-IN-4

    		Phosphodiesterase (PDE) Calcium Channel Inflammation/Immunology
    PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research [1].
    PDE1-IN-4
  • HY-120195A
    PF-04827736

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PF-04827736 (compound (S)-3) is a selective PDE1 inhibitor with IC50 values of 9.1 nM, 38 nM and 42 nM for PDE1B, PDE1C and PDE1A. PF-04827736 selectively inhibits human PDE1 over the other 10 superfamily members (PDE2-PDE11). PF-04827736 can be used for the study of cardiovascular disease [1].
    PF-04827736
  • HY-103493R
    TAK-915 (Standard)

    		Reference Standards Phosphodiesterase (PDE) Neurological Disease
    TAK-915 (Standard) is the analytical standard of TAK-915 (HY-103493). This product is intended for research and analytical applications. TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment [1] .
    TAK-915 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: